본문 바로가기
  • Home

Impact of GNB3, ADRB3, UCP2, and PPARγ-Pro12Ala polymorphisms on Boiogito response in obese subjects : A randomized, double-blind, placebo-controlled trial

  • Journal of Korean Medicine for Obesity Research
  • Abbr : J Korean Med Obes Res
  • 2012, 12(2), pp.28-43
  • Publisher : The Society of Korean Medicine for Obesity Research
  • Research Area : Medicine and Pharmacy > Korean Medicine

박정현 1 BOSE 2 Lim, Chi-Yeon ORD ID 3 Hojun Kim 4

1강남경희 한방병원 한방재활의학과
2동국대학교의학과 연구실
3동국대학교 의학대학원
4동국대학교 한방재활의학과

ABSTRACT

ObjectivesThe aim of the study was to investigate the efficacy of Boiogito for obesity. We examined the efficacy of boiogito for obese patients and we expected the reaction of Boiogito would vary according to the single uncleotide polymorphism(SNPs). Methods111 subjects(body mass index≥25m/kg²) were recruited and randomized to receive Boiogito(n=55) or Placebo(n=55) for 8weeks. Anthropometric factors, serum lipid profile, glucose, blood pressure(BP), pulse rate, resting metabolic rate and Koran version of obesity-related quality of life(KOQOL) scale measured at baseline and 8weeks. SNPs(ß3-adrenegic receptor(ADRB3), G protein ß3(GNB3), peroxisome proliferator activated receptor gamma 2 gene(PPAR-ɤ2), uncoupling protein(UCP2)) were conducted at baseline. Adverse reactions and safety outcome variables were also checked during trials. ResultsBoth groups showed significant improvement on obesity after treatment. Boiogito group decreased triglyceride then did control group and improved KOQOL. Boiogito showed a significant higher efficacy in C/T and T/T genotype of GNB3 gene / in Trp64 and Arg64 genotype of ADRB3 gene / in D/D genotype of UCP2 gene / in Pro/Pro genotype of PPAR-γ gene. ConclusionsBoiogito promoted obesity indexes without severe adverse reactions and proved its safety. Pharmacogenetical studies of Boiogito on obesity could be a effective method for the individualized treatment and prevention of obesity.

Citation status

* References for papers published after 2022 are currently being built.